国产长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床观察  

Combination Chemotherapy With Vinorelbine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：宋俊彪 路萍 

机构地区：[1]江苏省盐城市第一人民医院,江苏盐城224006

出　　处：《哈尔滨医药》2006年第6期2-4,共3页Harbin Medical Journal

摘　　要：目的观察国产长春瑞滨(盖诺,NVB)联合顺铂(DDP)治疗晚期非小细胞肺癌(N SCLC)化疗方案的疗效。方法有明确的病理和/或细胞学诊断的34例晚期N SCLC患者,运用NVB 25m g/m2,静滴d1,d8;DDP 25m g/m2,静滴d1,d2,d3,每21天为1周期。结果CR 0例,PR 14例(41.2%),SD 16例(47.1%),PD 4例(11.8%),有效率为41.2%(14/34)。不良反应主要为骨髓抑制和消化道反应。结论国产长春瑞滨和顺铂联合方案治疗晚期N SCLC,疗效较高且毒副反应可以耐受。Objective ：To evaluate of vinorelbine（NVB） and cisplatin on advanced non-small cell lung cancer（NSCLC）. Methods： 34 cases of cytologically and pathologically advanced NSCI.C were treated with combined chemotherapy including navelbine and cisplatin. NVB 25 mg/m^2IV,d1,d8; DDP25 mg/m^2IV d1, d2,d3,a cycle was 21 days. Results：There was no CR in patients treated with the rebimen,PR was 14 in 34 cases 41.2% ,SD was 16 cases（47. 1%） and PD 4 cases（11. 88%）. The side effects were mainly myleosup- pression and digestive tract reaction. Conclusion：Result showed that the combined chemotherapy was effective and safe in the treatment of advanced NSCI.C.

关 键 词：非小细胞肺癌 联合化疗 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]